Explore the evolving role of multikinase inhibitors in gastrointestinal malignancies. This Expert Review takes a deep dive into the use of targeted therapies for colorectal and hepatocellular cancers, as well as cholangiocarcinoma and gastrointestinal stromal tumors.
0.75 AMA PRA Category 1 Credit(s)™
Nov 8, 2019
Nov 8, 2020
Jordi Bruix, MD, PhDUniversity of Barcelona
Axel Grothey, MDWest Cancer Center
Memphis, Tennessee, United States
Scott Kopetz, MD, PhD, FACPUniversity of Texas
MD Anderson Cancer Center
Houston, Texas, United States
Multikinase Inhibitors in Gastrointestinal Malignancies: Emerging Options for Colorectal Cancer, Hepatocellular Carcinoma, Cholangiocarcinoma, and Gastrointestinal Stromal Tumor
This educational activity is designed for hematologists/oncologists, gastroenterologists, and other clinicians involved in the management of patients with gastrointestinal malignancies.
Upon completion of this activity, participants will:
- Have increased knowledge regarding the
- role of targeted therapies in advanced or metastatic gastrointestinal (GI) cancer
- regarding the emerging efficacy and safety data of targeted therapies in advanced or metastatic GI cancer
- Have greater competence related to
- incorporating targeted therapies into the advanced or metastatic GI cancer treatment algorithm
This educational activity is supported by Bayer HealthCare Pharmaceuticals, Inc.
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and prIME Oncology. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Estimated time to complete activity: 0.75 hour(s)
To contact Postgraduate Institute for Medicine please visit www.pimed.com.
This activity is jointly provided by Postgraduate Institute for Medicine and prIME Oncology.
Method of Participation
Disclosure of Relevant Financial Relationships
Postgraduate Institute for Medicine (PIM) and prIME Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Disclosure: Jordi Bruix, MD, PhD, has disclosed the following relevant financial relationships:
- Served as an advisor or consultant for: AbbVie; Adaptimmune; Arqule; Astra-Medimmune; Basilea; Bayer-Shering Pharma; Bio-Alliance; BMS; BTG-Biocompatibles; Eisai; Gilead; Incyte; Ipsen; Kowa; Lilly; MSD; Nerviano; Novartis; Quirem; Roche; Sanofi; Sirtex; Terumo
- Served as a speaker or a member of a speakers bureau for: Bayer-Shering Pharma; BTG-Biocompatibles; Eisai; Ipsen; Sirtex; Terumo
- Received grants for clinical research from: Bayer; BTG
Disclosure: Axel Grothey, MD, has disclosed the following relevant financial relationships:
- Served as an advisor or consultant for: Array; Bayer; Daiichi; Genentech-Roche; Taiho; Takeda
- Received grants for clinical research from: Array; Bayer; Daiichi; Genentech
Disclosure: Scott Kopetz, MD, PhD,FACP, has disclosed the following relevant financial relationships:
- Served as an advisor or consultant for: Amal Therapeutics; Amgen; AstraZeneca/MedImmune; Bayer Health; Biocartis; Boehringer Ingelheim; Boston Biomedical; EMD Serono; Genentech; Holy Stone; Karyopharm therapeutics; Lilly; Merck & Co.; Navire Pharma; Novartis; Pierre Fabre; Redx Pharma; Roche; Symphogen
- Received grants for clinical research from: Amgen; Array BioPharma; Biocartis; EMD Serono; Genentech/Roche; Guardant Health; Lilly; MedImmune; Novartis; Sanofi
- Owns less than 5% stock, stock options, or bonds from: MolecularMatch; Navire
Postgraduate Institute for Medicine Planners and Managers have disclosed no relevant financial relationships.
The employees of prIME Oncology have disclosed no relevant financial relationships.
This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.